Management ChangeMay 1, 2026, 09:29 AM
TRIB Appoints Head of North America Commercial Ops; Q4 Revenue $11.1M
AI Summary
Trinity Biotech plc announced the appointment of Jerry Lydon as Head of North America Commercial Operations, a strategic move to drive revenue and profitability following its Comprehensive Transformation Plan. The company reported Q4 2025 revenues of $11.1 million, broadly in line with guidance, and an improved gross margin of 35.2%. For the full year 2025, revenues were $43.8 million, with gross margin increasing to 38.6%, reflecting benefits from the ongoing transformation efforts despite overall revenue declines.
Key Highlights
- Jerry Lydon appointed Head of North America Commercial Operations.
- Q4 2025 revenue was $11.1M, down from $15.9M in Q4 2024.
- Q4 2025 gross margin increased to 35.2% from 30.8% year-on-year.
- Q4 2025 Adjusted EBITDA improved to negative $0.5M from negative $7.0M in Q4 2024.
- FY 2025 revenue was $43.8M, down from $61.6M in 2024.
- FY 2025 gross margin increased to 38.6% from 34.8% in 2024.
- TrinScreen™ HIV manufacturing scaled to targeted production levels by early Q2 2026.
- Premier HbA1c 9210™ platform received "Gold" classification for 2026.